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The stimulation of adipocyte-cyclase by isoproterenol decreases its sensitivity to adenosine, with, as a 
consequence, a decrease inits antilipolytic effect. The presence of insulin under conditions where its action 
on the phosphodiesterase ctivity is impaired, restores the responsiveness of adenylate-cyclase nd of 
lipolysis to adenosine. 
Adipocyte Adenylate-cyclase 
1. INTRODUCTION 
Insulin, prostaglandin EZ and adenosine are 
physiological inhibitors of lipolysis in rat fat cells 
[ 11. Lipolysis is controlled by at least two feedback 
loops. The first is proximal to the origin of the 
cascade and is mediated by adenosine, a degrada- 
tion product of cyclic AMP, whereas the second is 
more distal and is mediated by the prostanoids 
(prostaglandin EZ and prostacyclin) which are syn- 
thesized from arachidonate, one of the end- 
products of lipolysis [2]. Both loops interact with 
adenylate-cyclase, the first enzymic system of the 
cascade. Although the physiological role of the 
adenosine-dependent inhibition is recognized [3], 
that of the prostanoids is not clearly established 
[4,51. 
We showed that the sensitivity of adenylate- 
cyclase to prostaglandin Ei decreases by one order 
of magnitude (If& increasing from 20 to 200 nM), 
when the enzyme is stimulated by a ,&adrenergic 
agonist [6]. Under these conditions, the concentra- 
tion of prostaglandins, which can be estimated at 
3 nM for PGE2, is too low to exert a feedback con- 
trol on lipolysis [7]. Insulin is a hormonal inhibitor 
of lipolysis, which stimulates phosphodiesterase 
[8] and inhibits adenylate-cyclase activities [9,10]. 
We showed that the latter effect is not direct and 
Lipolysis Adenosine Insulin 
involves the participation of endogenous pro- 
stanoids whose activity is decoupled [6]. The pur- 
pose of this study is to investigate whether the sen- 
sitivity of adenylate-cyclase to adenosine is also 
decreased uring adrenergic stimulation, and if in- 
sulin restores the sensitivity in the absence of en- 
dogenous prostaglandins. This hypothesis is sup- 
ported by the fact that prostanoids and adenosine 
share a common site of action at the adenylate- 
cyclase level [I I]. Our results show that this is the 
case, and provide further information on the mode 
of action of insulin. 
2. MATERIALS AND METHODS 
Crystalline bovine B-grade insulin (INS) 
(25.5 IU/mg) and collagenase (200 IU/mg) were 
purchased form Calbiochem and Worthington 
Biochemicals, respectively. D, L-isoproterenol- 
HCI (IPNE) (lot l-5627) and bovine serum 
albumin fraction V (made fatty acid-free as in [ 121) 
were from Sigma. N6-(phenylisopropyl) adenosine 
(PIA) and adenosine-deaminase (ADA) were from 
Boerhinger. 3-(3,4dimethoxybenzyl)-2-imidazolidi- 
none (RO 7-2956) was kindly donated by Hoff- 
man-La-Roche (Base]). Indomethacin (INDO) was 
provided by Merck, Sharp and Dohme. Male 
Wistar rats (180 g) from Animalabo (Paris) were 
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kept at room temperature and given free access to 
food and water. They were decapitated and the 
epididymal fat pads were removed as quickly as 
possible, rinsed in ice-cold saline (NaCl 0.9%, 
w/v). The fat pads were cut into small fragments 
(SO-100 mg), and distributed among vials contain- 
ing Krebs-Ringer bicarbonate buffer 0.1 M 
(pH 7.4) with half the recommended (Ca2’) 
(1.3 mM) and 4% (w/v) fatty acid-free albumin. 
White fat cells were isolated by collagenase diges- 
tion as in [13]. 
Hormones, enzymes and drugs were made up 
freshly in buffer to the required final concentra- 
tions. RO 7-2956 and indomethacin were dissolved 
in a minimal volume of dimethyl sulfoxide which 
has no effect on lipolysis or on cyclic AMP 
production at the concentrations used. N6-(phenyl- 
isopropyl) adenosine was dissolved in a 
water-ethanol mixture, the final concentration of 
ethanol being less than 10e5 M. When indicated, 
the cells were first preincubated for 20 min at 37°C 
with indomethacin alone and then placed in a fresh 
medium containing indomethacin, the appropriate 
hormone, enzyme and drugs. Incubations lasted 
1 h for studies on lipolysis (free fatty acid release) 
or 6 min when the production of cyclic AMP was 
studied. 
Free fatty acids were extracted as in [14] and 
determined as in [ 151. Triglycerides were extracted 
as in [16]. Aliquots of total lipid extracts were 
saponified in KOH 4% (w/v) in 95% (v/v) ethanol 
for 30 min at 60°C. Glycerol was measured as in 
[17]. Cyclic AMP was assayed by the radio- 
immunological method as in [ 181 except that 
bound ligand was separated from the free ligand 
by polyethylene giycol precipitation (P. Mayeux, 
unpublished). 
The statistical differences were calculated by the 
Student’s I-test. The mean values + standard error 
of the mean (SEM), are given. 
3. RESULTS 
PIA is a very powerful inhibitor of lipolysis ef- 
fective also in the basal state. Lipolysis stimulated 
up to 400% when phosphodiesterase was inhibited 
with 1 mM RO 7.2956, was almost completely sup- 
pressed with 0.1 PM PIA (fig. 1). In contrast, when 
lipolysis was stimulated with 1 PM IPNE in the 
presence or absence of 1 mM RO 7.2956, PIA was 
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Fig. 1. Effect of PIA on lipolysis in adipose tissue, in the 
absence of IPNE, in the presence or absence of RO 
7.2956 (10m3 M). The mean values + SEM of 5 assays 
of free fatty acid release are presented after 1 h of 
incubation. The inhibition % due to PIA is indicated on 
the right ordinate. 
less effective up to PM (fig.2). The inhibition 
varied between 43% and 67% according to the 
experiments. 
In these experiments the action of PIA was 
superimposed to the action of endogenous 
adenosine and prostanoids. In order to study the 
action of PIA by itself on lipolysis stimulated by 
RO 7.2956 plus IPNE supplemented or not with 
INS, endogenous adenosine was destroyed with 
adenosine deaminase (1 rg/ml) and the formation 
of prostanoids was prevented with INDO 
(20 /cg/ml). Under these conditions, the following 
results were observed (fig.3): 
(i) After the destruction of endogenous 
adenosine and the prevention of the synthesis 
of prostanoids, insulin lost its antilipolytic 
activity; 
(ii) The addition of increasing concentrations of 
PIA decreased the lipolysis intensity, the in- 
hibitory effect reaching 50% for PM PIA; 
(iii) When PIA was applied in the presence of INS, 
inactive by itself, the slope of the inhibition 
curve was increased and PM PIA produced a 
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Fig.2. Effect of PIA on lipolysis in adipose tissue, in the 
presence of IPNE (10e6 M), in the presence or absence 
of RO 7.2956 (lo-’ M). The mean vaIues f SEM of 5 
assays of free fatty acid release are presented after I h of 
incubation. The inhibition 070 due to PIA is indicated on 
75% decrease in free fatty acid release; i.e., a 
50% enhancement of the own action of PIA, 
This effect of INS involved adenylate-cyclase, 
since RO 7.2956, at concentrations raised to 
1 PM, prevented whatever action at the 
phosphodiesterase l vel [ 191. 
Similar results were obtained on the production 
of cAMP (fig.4): in the absence of PIA and after 
suppression of the endogenous regulators 
(adenosine and prostanoids) INS did not decrease 
the CAMP accumulation after 6 min incubation. 
An almost complete inhibition of cyclic AMP ac- 
cumulation was obtained at 1 pM PIA in the 
absence of INS, whereas the same maximal inhibi- 
tion was reached at 0.1 PM PIA in the presence of 
INS. Here again, the slope of the curve was in- 
creased in the presence of INS. 
4. ~ISCUSSXON 
Our previous studies [6] were designed to assign 
the respective role of prostaglandins and of insulin 
PIA PIAIM) 
Fig.3. Effect of phenylisopropyladenosine (PIA) and 
insulin (100 /units/ml) on lipolysis in adipocytes 
stimulated by isoproterenol (low6 M) in the presence of 
RO 7.2956 (1O-3 M), indomethacin (20pg/ml) and 
adenosine deaminase (1 ~g/mI). The mean values k 
SEM of 6 assays of free fatty acid release are presented 
after 1 h of incubation. 
accumulated after 6 min are presented. 
Fig.4. Effect of phenylisopropyladenosine (PIA) and 
insulin (100 #units/ml) on cyclic AMP accumulation by 
adipocytes stimulated by isoproterenol ( 10m6 M), in the 
presence of RO 7.2956 (lO-3 M), indomethacin 
(20pg/ml) and adenosine deaminase (1 pgfml). The 
mean values f SEM of 3 assays of cyclic AMP 
in antilipolysis at the adenylate-cyclase l vel. Phos- 
phodiesterase activity was completely inhibited by 
3-isobutyl, I-methylxanthine which also prevented 
adenosine production from CAMP. Moreover, 
3-isobutyl, I-methylxanthine presented the advan- 
tage to compete with adenosine at the R receptor 
level [20]. Prostagl~din synthesis was impaired by 
phenelzine, which did not inhibit (as indomethacin 
did) the prostaglandin transport system [21], 
allowing the uptake and the action of exogenous 
prostaglandin. Under these conditions, in the 
presence of insulin, lo-times less PGEi was needed 
to induce a similar effect than in its absence, the 
dose-response curve being shifted to the left. 
The aim of these experiments was to test if the 
efficiency of adenosine, as an inhibitor, would be 
decreased, when the adenylate-cyclase was stimu- 
lated, and whether insulin could restore this effi- 
ciency. It was compulsory to replace 3-isobutyi, 
I-methyixanthine by a good inhibitor of phospho- 
diesterase activity, such as RO 7.2956, which 
would not interfere at the adenosine receptor level 
33 
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[22]. Endogenous adenosine, whose actual concen- 
tration was not determined, was destroyed by 
adenosine deaminase. The biosynthesis of pro- 
stanoids was prevented by indomethacin, a con- 
ventional inhibitor of prostaglandin synthetase. 
PIA was used as a substitute for adenosine: its own 
inhibitory action on cyclic AMP production and 
on free fatty acid release was concentration- 
dependent. Insulin which was inactive by itself at 
the adenylate-cyclase l vel was able to increase by 
50% the efficiency of PIA on cyclic AMP ac- 
cumulation and on lipolysis. At this stage of our 
experimentation, the following conclusions can be 
drawn: 
(9 
(ii) 
(iii) 
(iv) 
Insulin decreases lipolysis [ 191 and cyclic AMP 
accumulation [9] under conditions where 
phosphodiesterase is completely inhibited and 
adenylate-cyclase stimulated. This action, due 
to an inhibition of adenylate-cyclase activity, 
is not seen when the endogenous production 
of prostanoids and adenosine are suppressed 
([6] and this paper). 
The sensitivity of stimulated adenylate-cyclase 
to its feedback inhibitors is lower than in the 
basal state. 
Insulin restores the inhibitory potency of 
adenosine by an increase of its efficiency upon 
adenylate-cyclase (this paper) and of pro- 
stanoids by an increase of their apparent af- 
finity for the enzyme [6]. 
Insulin exerts its action at the same site as pro- 
stanoids and adenosine, cholera toxin treat- 
ment preventing the action of the three in- 
hibitors [l 11. The nature of the mediator of 
this insulin action is unknown. 
Our results are compatible with those previously 
reported in [23] and [24] recognizing the com- 
pulsory character of the presence of adenosine in 
the expression of the antilipolytic action of insulin. 
Nevertheless, their interpretation was opposite, 
they spoke about the potentiation by adenosine of 
insulin action. This concept, which seems tenable 
in the cases of glucose transport and lipid synthesis 
[25] is not appropriate in the case of the control of 
adenylate-cyclase activity. 
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